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Abstract 
Objective. Type 2 diabetes can be efficiently prevented by lifestyle intervention provided 
for people at high diabetes risk. The aim of this paper was to conduct a literature search 
on existing quality indicators for type 2 diabetes prevention and to collate and present a 
set of indicators that could be applied in European countries with different health care 
systems and cultures.
Methods. Scientific and grey literature was searched for relevant studies using electronic 
databases. We also hand searched previous systematic reviews and reference lists of rel-
evant articles. 
Results. The only publication identified was the report presenting the results from the IM-
AGE project. The IMAGE indicators were used as the basis for the proposed indicators. 
Conclusions. Publications on quality indicators of diabetes prevention programmes are 
scarce. The quality indicators presented here are a first step toward the definition of a 
core set of European indicators to monitor and improve the quality of diabetes preven-
tion.
INTRODUCTION
Diabetes is acknowledged by the World Health Orga-
nization to be one of the four major non-communicable 
diseases along with cardiovascular diseases, cancers, 
and respiratory diseases [1]. The need for actions and 
society-wide efforts to tackle the world-wide diabetes 
epidemic is well-recognized, and the role of prevention 
to contrast diabetes is stated “fundamental” [2].
Numerous clinical studies completed in different parts 
of the world and within differing ethnic populations and 
cultural frameworks have proven that type 2 diabetes is 
preventable. A lifestyle intervention aiming at relatively 
modest lifestyle changes provided to high-risk individu-
als has been shown to halve the risk of diabetes [3-5]. 
These efficacy trials have been followed by translational 
“real world” trials which have given further evidence 
about the effectiveness of diabetes prevention [6]. 
International Diabetes Federation (IDF) proposes 
opportunistic identification of undiagnosed type 2 
diabetes by undertaking stepwise screening program 
including risk identification based on individual risk 
factors or a risk score, followed by diagnostic testing. 
Opportunistic screening to facilitate early identification 
of diabetes is recognized as part of good quality care 
of type 2 diabetes. IDF does not support non-targeted 
screening for unidentified diabetes, especially in low-
resource settings [7]. 
In practice, screening to identify undiagnosed cases 
of diabetes inevitably leads also to identification of in-
dividuals at high diabetes risk but no diabetes (yet). We 
know that the development of diabetes via various stag-
es of insulin resistance and hyperglycaemia into overt 
diabetes can take 10 years or longer. This “lag period” is 
an important window of opportunity for preventive ac-
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tions. It offers the time to prevent or delay the develop-
ment of diabetes among these individuals at risk by life-
style modifications. Importantly, screening for impaired 
glucose tolerance followed by appropriate intervention 
has been suggested to be cost effective in a modelling 
study based on the results from published clinical trials 
and epidemiological studies [8] and in a recent system-
atic review on diabetes prevention interventions [9].
Therefore, interventions to prevent the development 
of diabetes in these high-risk individuals should be an 
integral part of a comprehensive diabetes plan and in-
cluded in clinical guidelines for diabetes management. 
However, clinical guidelines have been shown to im-
prove disease management only when introduced in the 
context of evaluation, and for that, quality indicators 
are needed. 
Quality assurance should be an integral part of all 
prevention programmes. Quality indicators for diabetes 
care have been developed and published by several or-
ganizations in different countries [10]. However, publi-
cations on quality management of diabetes prevention 
programmes are rare. As a result, prevention strategies 
and programmes frequently lack comprehensive, sys-
tematic follow-up and monitoring.  
The aim of this paper was to conduct a literature 
search on existing quality criteria and indicators for 
type 2 diabetes prevention and to collate and present a 
preliminary set of criteria that could be applied in Eu-
ropean countries with different health care systems and 
cultures.
METHODS
A review of the scientific literature and grey literature 
was performed to identify existing quality criteria and 
indicators for type 2 diabetes prevention. The following 
electronic databases were searched: 
• Academic Search Elite; 
• CINAHL;
• Web of Science Core Collection;
• MEDLINE (Ovid);
•  The Joanna Briggs Institute EBP Database; 
• Cochrane Database of Systematic Reviews; 
• Database of Abstracts of Reviews of Effects; 
• Cochrane Central Register of Controlled Trials; 
• Health Technology Assessment;
•   Applied Social Sciences Index and Abstracts (ASSIA);
•  ProQuest Health Management;
•  Social Services Abstracts;
• Worldwide Political Science Abstracts;
• Google;
• Google Scholar;
• NICE Evidence Search.
To identify potentially relevant quality criteria and 
indicators, a search strategy was developed in consul-
tation with an information specialist. The literature 
search strategy included the terms “quality assurance”, 
“quality indicator”, “good practice”, “best practice”, 
“quality standard”, “quality management” combined 
with “diabetes” and “prevention” and covered the time 
from 2000 to February 2015. Only publications in Eng-
lish were included. The titles, abstracts (when avail-
able), and the web sources were scanned, in order to 
identify relevant publications by two reviewers (JL and 
KW). We also hand searched reference lists of relevant 
articles and previous systematic reviews.  Publications 
that presented specified quality indicators for type 2 di-
abetes programs completed in health care setting were 
considered eligible.
In addition, some generally acknowledged diabetes 
management guidelines, e.g. the NICE guidance [11] 
that includes detailed recommendations also about 
how diabetes prevention should be arranged and what 
should be the targets for e.g. lifestyle change were con-
sulted for reference. The guidelines were reviewed in or-
der to check whether any important points that should 
be considered when proposing the quality indicators 
had been omitted.
RESULTS
Publications specifically presenting quality indicators 
for diabetes prevention proved to be scarce. The only 
publication identified was Pajunen et al. The “Qual-
ity and Outcome Indicators for Prevention of Type 2 
Diabetes in Europe – IMAGE” [12]. These indicators 
had been developed by a group of specialist represent-
ing different professional groups from several Europe-
an countries. Indicators were produced by the expert 
group in consensus meetings and further developed by 
combining evidence and expert opinion.
Indicators of IMAGE (Development and Implemen-
tation of a European Guideline and Training Standards 
for Diabetes Prevention) were developed along with 
the European evidence-based guideline for the preven-
tion of type 2 diabetes [13] and the Toolkit for diabetes 
prevention [14]. Therefore, the IMAGE indicators are 
closely linked to the guideline standards and are intend-
ed to be used in conjunction with them. These products 
of the multidisciplinary consortium IMAGE were used 
as the starting point for the definition of the indicators 
in this project. This is a first step toward the definition 
of a core set of European indicators to improve the 
quality of diabetes prevention with different health care 
systems and cultures.
The suggested quality indicators for diabetes preven-
tion are presented in Table 1. As in the original IMAGE 
publication, the indicators are arranged according to 
operational level and categorized as structure/process 
and outcome indicators, as suggested by Donabedian 
[15]. The structure indicators relate to material and hu-
man resources, as well as organizational structure. The 
process indicators describe how activities are undertak-
en to implement prevention. The outcome indicators 
are related to the actual clinical results of the preventive 
interventions. These classifications help the user to per-
ceive that good quality is a multifaceted phenomenon 
and that there are different level operators that have 
differing responsibilities, and good practices in all levels 
are needed for good overall outcome. 
The role of the “macro” level (national-level decision 
makers) is to generate the prerequisites for diabetes 
prevention. Five of the 10 macro-level indicators pro-
posed by IMAGE are included also in the present set of 
indicators even though they are not under the control 
of health care operators (such as “Prevalence of dia-
Quality indicators for diabetes prevention
M
o
n
o
g
r
a
p
h
ic
 s
e
c
t
io
n
189
betes in the population” or “Prevalence of overweight, 
obesity and abdominal obesity in population”). The rea-
son for the inclusion is that they are vital information 
for example to estimate personnel needs and to direct 
resources where they are most needed. The responsi-
bility of the “meso” level (primary health care level) is 
the organization of the activities on diabetes preven-
tion in municipalities, health districts, health care cen-
ters, occupational care, private sector, local level non-
governmental organizations. Altogether 15 of the 19 
meso-level indicators from IMAGE were included. The 
indicators are frequently interconnected, for example 
“Validated diabetes risk assessment tools are available 
to health care providers” is a prerequisite for “Propor-
tion of the population screened (by health care pro-
vider) per year”. The responsibility of the “micro” level 
(individual-level prevention work) is the conduct of ac-
tual preventive work in different sectors (public, private 
and occupational health). For example, the assessment 
of individual´s risk factor profile is a prerequisite for 
successful intervention, as well as the definition of the 
structure and content of the interventions. In addition, 
Table 1
Quality indicators for diabetes prevention programmes and activities
Type Description
Macro level
Structure/Process In activities of diabetes prevention, ethnic minorities and low socio-economic groups are considered
Outcome Prevalence of diabetes in the population
Outcome Percentage of the population physically inactive
Outcome Prevalence of overweight, obesity and abdominal obesity in population
Outcome Percentage of population following national recommendations on nutrition
Meso level
Structure/Process Screening protocols to identify high-risk persons have been evaluated at national level
Structure/Process Validated diabetes risk assessment tools are available to health care providers
Structure/Process Information technology systems supporting the implementation of screening are available at health care provider 
level
Outcome Proportion of the population screened (by health care provider) per year
Outcome The percentage of identified high-risk individuals remitted to diagnostic procedures
Outcome The percentage of identified high-risk individuals remitted to lifestyle interventions
Structure/Process High-risk prevention strategies are included in the education of the health care professionals
Structure/Process Defined clinical pathways exist for the health care provider to deal with individuals at risk for diabetes
Structure/Process Multidisciplinary approach for interventions is supported by the health care provider
Structure/Process Health care providers are collaborating with other players in health promotion
Structure/Process Medical record system supports interventions for chronic disease prevention
Outcome The percentage of remitted high-risk individuals participating in lifestyle interventions
Outcome Proportion of individuals dropping out of interventions
Outcome Proportion of high-risk individuals in interventions achieving clinically significant changes in risk factors at 1 year 
follow-up
Outcome Diabetes incidence rate among high-risk individuals in interventions at health care provider
Micro level
Structure/Process Individual’s risk factor profile is assessed
Structure/Process Individual’s motivation for behavioural changes is discussed
Structure/Process Structure and content of the interventions have been defined at individual level
Structure/Process Individualized targets for interventions have been established
Structure/Process Plan for follow-up is defined
Outcome Proportion of planned intervention visits completed over 1 year
Outcome Weight change over 1 year
Outcome Change in waist circumference over 1 year
Outcome Change in glucose over 1 year
Outcome Change in the quality of nutrition over 1 year
Outcome Change in physical activity over 1 year
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plans for individual follow-up have to be defined before 
their achievement can be recorded. All 11 indicators 
were included also in the current set of criteria.
DISCUSSION
Evidence-based clinical guidelines are important in 
order to harmonize practices in health care, but their 
existence does not necessarily lead to good quality care. 
Intuitively, quality indicators can be deduced from clini-
cal guidelines. However, clinical guidelines have been 
shown to improve disease management only when in-
troduced in the context of evaluation [16]. As present-
ed in a recent systematic review and meta-analysis by 
Dunkley, et al., prevention of type 2 diabetes is effective 
also in the “real world”. Furthermore, they showed that 
adherence to the IMAGE guideline recommendations 
indeed is associated with the effectiveness of the diabe-
tes prevention interventions [6]. 
Our literature review showed that there are not many 
published quality indicators specifically focusing on type 
2 diabetes prevention. It is possible that our literature 
search protocol failed to identify relevant publications. 
For example, we had to limit our search to include only 
indicators published in English language. However, 
more likely is that as diabetes prevention especially in 
real-life health care setting is a relatively young research 
field, there simply are no published quality indicators. 
We decided to focus on published indicators as it is rec-
ommended that whenever possible, existing indicators 
should be reviewed, adapted, and tested rather than go-
ing through the whole process of creating new indica-
tors [17, 18]. Also, we chose not to present absolute 
standards or cut-off values for indicators, as these needs 
to be decided according to local contexts and circum-
stances. IMAGE project revealed challenges to assign 
the target values for indicators because of lack of data 
on the general population [12].
The indicators are not meant to give definitive an-
swers but provide tools to achieving better understand-
ing of the system and to alert about possible areas of 
improvement. It should also be noted that even good 
indicators cannot capture all domains of quality and es-
pecially the qualitative and subjective elements need to 
be explored by other methods.
The quality indicators presented here are a first step 
toward the definition of a core set of European indica-
tors to monitor, evaluate, and improve the quality of 
diabetes prevention. The quality indicators were devel-
oped for different prevention strategies: population-
level prevention strategies, screening for high risk and 
high-risk prevention strategies. They may constitute 
a tool for decision makers, health care providers and 
health care personnel to assure the minimum level of 
quality assurance recommended for diabetes preven-
tion programmes. The adoption of an agreed core set of 
quality indicators might help to decrease inequalities in 
health and to improve diabetes prevention within and 
between European countries.
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